The shape effect of reconstituted high-density lipoprotein nanocarriers on brain delivery and Aβ clearance

[1]  M. Stecker,et al.  Amyloid toxicity in Alzheimer’s disease , 2018, Reviews in the neurosciences.

[2]  C. Rowe,et al.  Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions , 2018, Nature Reviews Neurology.

[3]  Enrico Guarnera,et al.  Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease. , 2018, Trends in pharmacological sciences.

[4]  Bin Zhang,et al.  Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation , 2017, Nature Medicine.

[5]  C. Masters,et al.  A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain , 2017, Nature Reviews Neurology.

[6]  H. Budka,et al.  SAMP8 mice as a neuropathological model of accelerated brain aging and dementia: Toshio Takeda's legacy and future directions , 2017, Neuropathology : official journal of the Japanese Society of Neuropathology.

[7]  Michael S Valic,et al.  Tailored theranostic apolipoprotein E3 porphyrin-lipid nanoparticles target glioblastoma , 2017, Chemical science.

[8]  Xin-guo Jiang,et al.  Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis , 2017, Nature Communications.

[9]  G. Fricker,et al.  Development and characterization of novel highly‐loaded itraconazole poly(butyl cyanoacrylate) polymeric nanoparticles , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[10]  A. Minihane,et al.  A randomized trial and novel SPR technique identifies altered lipoprotein-LDL receptor binding as a mechanism underlying elevated LDL-cholesterol in APOE4s , 2017, Scientific Reports.

[11]  Jin-bo Yin,et al.  Regulatory factor X1 depresses ApoE-dependent Aβ uptake by miRNA-124 in microglial response to oxidative stress , 2017, Neuroscience.

[12]  M. Bentivoglio,et al.  Novel functionalization strategies of polymeric nanoparticles as carriers for brain medications. , 2017, Journal of biomedical materials research. Part A.

[13]  M. G. Savelieff,et al.  Towards an understanding of amyloid-β oligomers: characterization, toxicity mechanisms, and inhibitors. , 2017, Chemical Society reviews.

[14]  M. Khrestchatisky,et al.  Use of LDL receptor—targeting peptide vectors for in vitro and in vivo cargo transport across the blood‐brain barrier , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  C. Thaxton,et al.  Lipoproteins and lipoprotein mimetics for imaging and drug delivery. , 2016, Advanced drug delivery reviews.

[16]  G. Yi,et al.  A high-density lipoprotein-mediated drug delivery system. , 2016, Advanced drug delivery reviews.

[17]  Jianrong Xu,et al.  Biomimetic ApoE-Reconstituted High Density Lipoprotein Nanocarrier for Blood-Brain Barrier Penetration and Amyloid Beta-Targeting Drug Delivery. , 2016, Molecular pharmaceutics.

[18]  J. Simonsen.  Evaluation of reconstituted high-density lipoprotein (rHDL) as a drug delivery platform - a detailed survey of rHDL particles ranging from biophysical properties to clinical implications. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[19]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[20]  X. Qu,et al.  Ceria/POMs hybrid nanoparticles as a mimicking metallopeptidase for treatment of neurotoxicity of amyloid-β peptide. , 2016, Biomaterials.

[21]  Sara Linse,et al.  Atomic Resolution Structure of Monomorphic Aβ42 Amyloid Fibrils. , 2016, Journal of the American Chemical Society.

[22]  Wai Hang Cheng,et al.  Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice. , 2016, Biochimica et biophysica acta.

[23]  L. Yao,et al.  Nanoformulated alpha-mangostin ameliorates Alzheimer's disease neuropathology by elevating LDLR expression and accelerating amyloid-beta clearance. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[24]  Y. E. Chen,et al.  High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. , 2016, ACS nano.

[25]  Gang Zheng,et al.  GM1-Modified Lipoprotein-like Nanoparticle: Multifunctional Nanoplatform for the Combination Therapy of Alzheimer's Disease. , 2015, ACS nano.

[26]  Ying Li,et al.  Shape effect in cellular uptake of PEGylated nanoparticles: comparison between sphere, rod, cube and disk. , 2015, Nanoscale.

[27]  Yanan Liu,et al.  Sialic acid (SA)-modified selenium nanoparticles coated with a high blood-brain barrier permeability peptide-B6 peptide for potential use in Alzheimer's disease. , 2015, Acta biomaterialia.

[28]  Y. E. Chen,et al.  The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties[S] , 2015, Journal of Lipid Research.

[29]  Michel Goedert,et al.  Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein , 2015, Science.

[30]  Michael T. Colvin,et al.  High Resolution Structural Characterization of Aβ42 Amyloid Fibrils by Magic Angle Spinning NMR , 2015, Journal of the American Chemical Society.

[31]  G. Zheng,et al.  Learning from biology: synthetic lipoproteins for drug delivery. , 2015, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[32]  M. Heneka,et al.  Innate immunity in Alzheimer's disease , 2015, Nature Immunology.

[33]  J. Hardy,et al.  Apolipoprotein E in Alzheimer's disease: an update. , 2014, Annual review of neuroscience.

[34]  Jun Chen,et al.  Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer's disease by accelerating the clearance of amyloid-beta. , 2014, ACS nano.

[35]  J. Weuve,et al.  Alzheimer disease in the United States (2010–2050) estimated using the 2010 census , 2013, Neurology.

[36]  C. Shad Thaxton,et al.  Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery. , 2013, Advanced drug delivery reviews.

[37]  C. Kuan,et al.  Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood–brain barrier , 2013, Proceedings of the National Academy of Sciences.

[38]  Wenli Zhang,et al.  Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins. , 2013, Biomaterials.

[39]  Xiaogang Qu,et al.  Using Graphene Oxide High Near‐Infrared Absorbance for Photothermal Treatment of Alzheimer's Disease , 2012, Advanced materials.

[40]  D. Holtzman,et al.  Low-density Lipoprotein Receptor Represents an Apolipoprotein E-independent Pathway of Aβ Uptake and Degradation by Astrocytes* , 2012, The Journal of Biological Chemistry.

[41]  Yanyu Xiao,et al.  Structure and remodeling behavior of drug-loaded high density lipoproteins and their atherosclerotic plaque targeting mechanism in foam cell model. , 2011, International journal of pharmaceutics.

[42]  B. Hyman,et al.  Amyloid-dependent and amyloid-independent stages of Alzheimer disease. , 2011, Archives of neurology.

[43]  J Bruce German,et al.  Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures. , 2011, ACS nano.

[44]  A. Kurz,et al.  Amyloid clearance as a treatment target against Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[45]  Ralph Weissleder,et al.  Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles. , 2010, Bioconjugate chemistry.

[46]  Tom Maniatis,et al.  Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice , 2009, Proceedings of the National Academy of Sciences.

[47]  H. Lashuel,et al.  The Ratio of Monomeric to Aggregated Forms of Aβ40 and Aβ42 Is an Important Determinant of Amyloid-β Aggregation, Fibrillogenesis, and Toxicity* , 2008, Journal of Biological Chemistry.

[48]  M Ferrari,et al.  The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. , 2008, Journal of biomechanics.

[49]  D. Butterfield,et al.  The senescence-accelerated prone mouse (SAMP8): A model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer's disease , 2005, Experimental Gerontology.

[50]  M. Prévost,et al.  Apolipoprotein E‐low density lipoprotein receptor binding: Study of protein–protein interaction in rationally selected docked complexes , 2004, Proteins.

[51]  Xudong Huang,et al.  Cytosolic β-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease , 2003, The Lancet.

[52]  G. Krafft,et al.  In Vitro Characterization of Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis* , 2003, The Journal of Biological Chemistry.

[53]  L. K. Baker,et al.  Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.

[54]  A Rostagno,et al.  Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. , 2000, The Biochemical journal.

[55]  P. Lansbury,et al.  Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? , 1993, Cell.